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Abstract
Background: Recently, necrotizing fasciitis has been reported in patients treated with bevacizumab, usually
secondary to wound healing complications, gastrointestinal perforations, or fistula formation. The risk of invasive
Haemophilus influenzae type b infection is significantly increased in immunocompromised hosts. However,
necrotizing fasciitis due to Haemophilus influenzae type b in a patient treated with combined bevacizumab and
chemotherapy has not been previously reported.
Case presentation: A 59-year-old woman was admitted to the intensive care unit after sudden onset of fever, chills,
and right thigh pain. She received chemotherapy with fluorouracil, irinotecan, and bevacizumab for colon cancer
10 days prior to admission. The advancing erythematous margin and her worsening clinical condition prompted us to
suspect necrotizing fasciitis and consult the orthopedics department for a fascia biopsy and debridement. Surgical
exploration revealed a murky dishwater-colored pus exudate from the incision site and the lack of a shiny appearance
of the fascia that also suggested necrotizing fasciitis. After 2 days, the final results of the blood and exudate cultures
confirmed the presence of Haemophilus influenzae type b. A diagnosis of necrotizing fasciitis due to Haemophilus
influenzae type b was made. The patient required recurrent surgical debridement and drainage, but she recovered
from the septic shock.
Conclusions: We report a case of necrotizing fasciitis due to Haemophilus influenzae type b in a patient without injury
and with rectal cancer treated with combined bevacizumab and chemotherapy. Physicians should consider invasive
Haemophilus influenzae type b disease in the presence of necrotizing fasciitis in patients treated with this combined
treatment modality.
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Background
Bevacizumab is an antibody designed to inhibit vascular
endothelial growth factor, which is involved in blood
vessel formation, and used primarily in the cancer field
for the treatment of colorectal cancer to prevent the for-
mation of blood vessels that feed tumors. Recently,
necrotizing fasciitis has been reported in patients treated
with bevacizumab, including some fatal cases [1]. How-
ever, necrotizing fasciitis usually develops secondary to
wound healing complications, gastrointestinal perfora-
tions, or fistula formation. Here, we report a case of nec-
rotizing fasciitis due to Haemophilus influenzae type b
(Hib) in a patient without injury and with rectal cancer
treated with combined bevacizumab and chemotherapy.
Case presentation
A 59-year-old woman was admitted to the intensive care
unit after sudden onset of fever, chills, and right thigh
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pain. She had undergone low anterior resection for
colon cancer 2 years earlier. After local recurrence, she
underwent radiation therapy (30 Gy) for spinal metasta-
sis followed by chemotherapy, which commenced 6 months
prior to admission to the intensive care unit. She received
chemotherapy with fluorouracil, irinotecan, and bevacizu-
mab 10 days prior to admission. She did not have a history
of previous injury or the presence of other risk factors for
necrotizing fasciitis such as a decubitus ulcer, diabetes, or
liver cirrhosis. Her medications included a 5-HT3 receptor
antagonist, which is an antiemetic, and a proton pump
inhibitor; however, her medications did not include
non-steroidal anti-inflammatory drugs, immunosup-
pressive drugs, or corticosteroids.
She was hypotensive, tachycardic, and tachypneic in the
emergency room. The results of the physical examination
were normal except for erythema in her right thigh. She
had no previous injuries. Hemoglobin level was 118 g/L
with a white blood cell count of 2.1 × 109 cells/L and a
platelet count of 1.3 × 1011 cells/L. Blood urea nitrogen
was 18.9 mmol/L, creatinine was 318.2 μmol/L, and
C-reactive protein was 3.8 × 106 μg/L. The results of
other blood tests and urinalysis were normal. Com-
puted tomography of the chest, abdomen, and pelvis
showed normal results. Septic shock was suspected
and managed accordingly with supportive measures,
such as the use of a vasopressor and supplemental
oxygen. Blood cultures were collected, and empirical
treatment with meropenem (1 g every 12 hours) and
vancomycin (1 g daily) were initiated, adjusted to renal
dysfunction. The advancing erythematous margin and her
worsening clinical condition prompted us to suspect nec-
rotizing fasciitis and consult the orthopedics department
for a fascia biopsy and debridement. Surgical exploration
revealed a murky dishwater-colored pus exudate from the
incision site and the lack of a shiny appearance of the
fascia that also suggested necrotizing fasciitis. The biopsy
of the frozen section showed acute necrotizing suppura-
tive inflammation, and extensive debridement was per-
formed. Gram staining of the exudates from the infected
site showed the presence of gram-negative rods. On the
basis of all of this information, we formally diagnosed the
patient with necrotizing fasciitis. On the following day,
gram-negative rods were also isolated from the blood cul-
tures. After 2 days, the final results of the blood and exudate
cultures confirmed the presence of β-lactamase-negative
Hib that was susceptible to ampicillin, cefotaxime, ciproflox-
acin, and imipenem. The histopathological findings of the
debrided tissue were compatible with a diagnosis of necro-
tizing fasciitis due to Hib.
The patient required recurrent surgical debridement
and drainage, but she recovered from the septic shock.
The treatment was changed to ampicillin, and she re-
ceived intravenous ampicillin for a total of 51 days because
of residual intermuscular abscesses. She recovered com-
pletely and was discharged from the hospital 65 days after
admission. Necrotizing fasciitis did not recur; however,
she died of metastatic colorectal cancer 6 months after
discharge.
Discussion
Necrotizing fasciitis is a rare but life-threatening infec-
tion of the soft tissue that is characterized by rapidly
spreading necrosis of the superficial fascia and subcuta-
neous tissue. Immunocompromised and diabetic patients
are at a higher risk of developing necrotizing fasciitis [2].
Although bevacizumab suppresses the immune system
[3], chemotherapy administered concurrently with beva-
cizumab is more likely to be responsible for immune
suppression. This combined treatment also contributes
to impaired wound healing. Furthermore, one of the
pathophysiologic mechanisms of necrotizing fasciitis is
subcutaneous artery thrombosis and tissue ischemia, to
which bevacizumab can contribute [4]. Therefore, the com-
bined treatment modality of bevacizumab and chemother-
apy is likely to place patients at an increased risk of
developing necrotizing fasciitis. Despite the fact that necro-
tizing fasciitis is a rare complication, affecting only 1 in 5000
bevacizumab users, physicians should bear in mind the risk
of necrotizing fasciitis when prescribing bevacizumab.
In a comprehensive safety review conducted by the
company Roche, 52 case reports of serious necrotizing
fasciitis were identified that occurred between November
1997 and September 2012 in patients treated with bev-
acizumab for cancer [5]. The majority of the patients
described in case reports have had gastrointestinal per-
forations, fistula formation, or wound healing compli-
cations preceding the development of necrotizing fasciitis
[6-8]. However, in the present case, the patient had no
previous injury or risk factor for necrotizing fasciitis such
as a decubitus ulcer, diabetes, or liver cirrhosis; her recent
chemotherapy was her primary risk for necrotizing fasci-
itis. These findings suggest a possible association between
necrotizing fasciitis and the recent combined treatment of
chemotherapy and bevacizumab in the absence of a previ-
ous injury.
It is of particular interest that Hib caused the necrotiz-
ing fasciitis in the present case. Prior to routine Hib vac-
cination, Hib was a well-known cause of invasive diseases,
such as meningitis and pneumonia with bacteremia, in
children younger than 2 years. However, the incidence of
invasive H. influenzae disease, especially among persons
aged over 65 years, and invasive non-typable H. influenzae
disease has increased from 1996 to 2004 [9]. The risk of
invasive Hib infection in adults is significantly increased
by multiple myeloma and chronic renal failure [10]. Other
factors conferring increased risk for H. influenzae infec-
tion include underlying immunocompromising conditions
Ugai et al. BMC Infectious Diseases 2014, 14:198 Page 2 of 3
http://www.biomedcentral.com/1471-2334/14/198
such as complement deficiency, hypogammaglobulinemia,
sickle cell anemia, functional asplenia, malignancy, and
human immunodeficiency virus infection [11,12]. Al-
though the association between bevacizumab and invasive
Hib infection remains unclear, we caution physicians to
consider invasive Hib disease in patients treated with the
combination of bevacizumab and chemotherapy.
A review of the current literature resulted in only 4 re-
ported cases of necrotizing fasciitis caused by Hib. The
first reported case occurred in a 13-month-old infant
[13], while the second case occurred in an 81-year-old
man with diabetes mellitus [14]. A 64-year-old woman
who developed necrotizing fasciitis of her chest wall sec-
ondary to the epiglottitis represented the third case [15].
In the fourth case, a 44-year-old man developed necro-
tizing fasciitis of the right lower extremity after intra-
muscular injections of paracetamol in his right buttock
[16]. Including our case, all of the patients with necrotiz-
ing fasciitis due to Hib made a full recovery. Hib merits
additional consideration when deciding on appropriate,
empiric antimicrobial therapy as an adjunct to surgical
intervention for necrotizing fasciitis, especially in im-
munocompromised patients treated with combined bev-
acizumab and chemotherapy.
Conclusions
We report a case of necrotizing fasciitis due to Hib in a
patient without injury and with rectal cancer treated
with combined bevacizumab and chemotherapy. Physi-
cians should consider invasive Hib disease in the pres-
ence of necrotizing fasciitis in patients treated with this
combined treatment modality.
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